Almac Clinical Technologies, a member of the Almac Group, has announced the launch of its IXRS3 Partnership Network for biopharmaceutical sponsors, which aims to accelerate the development and delivery of innovative eClinical solutions.
Almac Clinical Technologies has over 25 years’ experience of working in partnership with specialist technology and service companies and understands that the interoperability of eClinical data systems is a priority for biopharmaceutical sponsors.
This partnership network gives sponsors and CROs the opportunity to share data and solutions to build a more inclusive clinical trial experience for all sites and patients.
George Tiger, Global Vice President of Almac Clinical Technologies Global Business Development, said: “Managing a mix of technologies throughout the course of a clinical trial is a common pain point for sponsors and service providers. Clinical technology companies who can demonstrate flexibility and interoperability can make the study build process and support more seamless, more transparent, and more cost-effective for sponsors and sites.
We look forward to growing this network with more partners as we strive to improve interoperability
“IXRS3 is the most trusted Interactive Response Technology platform in the industry and our aim is to build the most in-depth and innovative partnership network in the eClinical space.
“We are thrilled that some of the most innovative names in the industry have already joined the Partnership Network including Veeva, THREAD, Kayentis, N-SIDE, and ESMS Global. Their expertise spans clinical development cloud software, eCOA, decentralised clinical trials, clinical supply planning and optimisation, and medical monitoring.”
Mike Hutton, the Head of Partnerships and Strategic Alliances at ACT concluded: “We share an important goal with our trusted partners to provide our sponsors, sites, and patients with the best eClinical technology and services in the industry, and we can do it much better together.
“We look forward to growing this network with more partners as we strive to improve interoperability, making clinical trials easier to conduct for our sites and sponsors and participation easier for patients."
